Dana Johnson, MD
Cardiovascular Disease · Maywood, ILNPI 1235556671
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (39.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Abbott at 29.8% of the total. 2025 is the largest year on record at $41,676, more than ten times the $612 reported in 2019. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $253.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$31K
- Medtronic$30K
- Biotronik Inc.$17K
- Biosense Webster, Inc.$11K
- Boston Scientific$11K
- Altathera Pharmaceuticals LLC$2K
- plus $2K from 18 others
Across 1 payment — averaging $28,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$29K
What the payments were for
- Consulting fees$16,53816%
- Speaking & faculty fees$8,8008%
- Grants$40,41739%
- Travel & lodging$21,10620%
- Food & beverage$15,75915%
- Education$9361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $30,839 |
| Medtronic | 171 | $29,834 |
| Biotronik Inc. | 101 | $16,992 |
| Biosense Webster, Inc. | 33 | $10,905 |
| Boston Scientific | 32 | $10,691 |
| Altathera Pharmaceuticals LLC | 3 | $2,263 |
| Medical Device Business Services, Inc. | 9 | $836 |
| BD | 4 | $277 |
| Atricure, Inc. | 1 | $178 |
| Cardiva Medical, Inc. | 3 | $131 |
| Edwards Lifesciences | 2 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $92 |
| Johnson & Johnson | 3 | $85 |
| Abiomed | 1 | $70 |
| Terumo Medical Corporation | 2 | $52 |
| Novartis | 2 | $40 |
| Boehringer Ingelheim | 2 | $39 |
| ZOLL Circulation Inc | 1 | $28 |
| Getinge USA Sales, LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Cordis US CORP. | 1 | $17 |
| EKOS Corporation | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$7,884
- GENERAL BRADY$5,000
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$3,750
- Sotalol Hydrochloride$2,263
- ENSITE$1,900
- ENSITE PRECISION$1,238
- GENERAL - THERAPIES$1,061
- SPHERE-9$638
- SelectSecure$600
- BioMonitor$581
- Carto 3 System$559
- Acticor 7 VR-T DX$493
- Solia$469
- COBALT DR MRI SURESCAN$428
- Rivacor 7 DR-T$346
- Edora 8 DR-T$346
- AFFERA MAPPING SYSTEM$291
- Micra$268
- EnSite Precision Cardiac Mapping System$239
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$178
How this compares
$103,555 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $131,090 |
| XareltoRivaroxaban | 13 | $17,868 |
| Flecainide Acetate | 38 | $928 |
| Metoprolol Succinate | 59 | $797 |
| Amiodarone Hcl | 33 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $85 | $17,86813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Maywood
- Niraj VarmaMaywood$522K
- Mark RabbatMaywood$363K
- Smit VasaiwalaMaywood$264K
- Clifford KavinskyMaywood$260K
- Gregory MacalusoMaywood$165K
- Erin CoglianeseMaywood$36K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.